T-Cell Response and Antibody Production Induced by the COVID-19 Booster Vaccine in Japanese Chronic Kidney Disease Patients Treated with Hemodialysis

Ayumi Yoshifuji; Masataro Toda; Munekazu Ryuzaki; Emi Oyama; Kan Kikuchi; Toru Kawai; Ken Sakai; Masayoshi Koinuma; Kazuhiko Katayama; Takashi Yokoyama; Yuki Uehara; Norio Ohmagari; Yoshihiko Kanno; Hirofumi Kon; Toshio Shinoda; Yaoko Takano; Junko Tanaka; Kazuhiko Hora; Yasushi Nakazawa; Naoki Hasegawa; Norio Hanafusa; Fumihiko Hinoshita; Keita Morikane; Shu Wakino; Hidetomo Nakamoto; Yoshiaki Takemoto

doi:10.3390/vaccines11030653

T-Cell Response and Antibody Production Induced by the COVID-19 Booster Vaccine in Japanese Chronic Kidney Disease Patients Treated with Hemodialysis

Ayumi Yoshifuji, Masataro Toda, Munekazu Ryuzaki, Emi Oyama, Kan Kikuchi, Toru Kawai, Ken Sakai, Masayoshi Koinuma, Kazuhiko Katayama, Takashi Yokoyama, Yuki Uehara, Norio Ohmagari, Yoshihiko Kanno, Hirofumi Kon, Toshio Shinoda, Yaoko Takano, Junko Tanaka, Kazuhiko Hora, Yasushi Nakazawa, Naoki HasegawaNorio Hanafusa, Fumihiko Hinoshita, Keita Morikane, Shu Wakino, Hidetomo Nakamoto, Yoshiaki Takemoto

Research output: Contribution to journal › Article › peer-review

7 Citations (Scopus)

Abstract

Humoral and cellular responses are critical in understanding immune responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination. Here, we evaluated these responses in hemodialysis (HD) patients after the booster vaccination. SARS-CoV-2 immunoglobulin (IgG) levels, neutralizing antibody titers, and the T-SPOT^®.COVID test (T-SPOT) were measured prior to, three weeks after, and three months after the booster administration. The HD group had significantly higher SARS-CoV-2 IgG levels and neutralizing antibody titers against the original strain at three weeks and three months after the booster vaccination compared to the control group, albeit the HD group had lower SARS-CoV-2 IgG levels and neutralizing antibody titers before the booster administration. Moreover, the HD group had significantly higher T-SPOT levels at all three time points compared to the control group. The HD group also had significantly higher local and systemic adverse reaction rates than the control group. By booster vaccination, HD patients could acquire more effective SARS-CoV-2-specific humoral and cellular immunity than the control group.

Original language	English
Article number	653
Journal	Vaccines
Volume	11
Issue number	3
DOIs	https://doi.org/10.3390/vaccines11030653
Publication status	Published - 03-2023
Externally published	Yes

All Science Journal Classification (ASJC) codes

Immunology
Pharmacology
Drug Discovery
Infectious Diseases
Pharmacology (medical)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3390/vaccines11030653

Cite this

Yoshifuji, A., Toda, M., Ryuzaki, M., Oyama, E., Kikuchi, K., Kawai, T., Sakai, K., Koinuma, M., Katayama, K., Yokoyama, T., Uehara, Y., Ohmagari, N., Kanno, Y., Kon, H., Shinoda, T., Takano, Y., Tanaka, J., Hora, K., Nakazawa, Y., ... Takemoto, Y. (2023). T-Cell Response and Antibody Production Induced by the COVID-19 Booster Vaccine in Japanese Chronic Kidney Disease Patients Treated with Hemodialysis. Vaccines, 11(3), Article 653. https://doi.org/10.3390/vaccines11030653

@article{5089325dbb2f4ac0a186d224a7cdc453,

title = "T-Cell Response and Antibody Production Induced by the COVID-19 Booster Vaccine in Japanese Chronic Kidney Disease Patients Treated with Hemodialysis",

abstract = "Humoral and cellular responses are critical in understanding immune responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination. Here, we evaluated these responses in hemodialysis (HD) patients after the booster vaccination. SARS-CoV-2 immunoglobulin (IgG) levels, neutralizing antibody titers, and the T-SPOT{\textregistered}.COVID test (T-SPOT) were measured prior to, three weeks after, and three months after the booster administration. The HD group had significantly higher SARS-CoV-2 IgG levels and neutralizing antibody titers against the original strain at three weeks and three months after the booster vaccination compared to the control group, albeit the HD group had lower SARS-CoV-2 IgG levels and neutralizing antibody titers before the booster administration. Moreover, the HD group had significantly higher T-SPOT levels at all three time points compared to the control group. The HD group also had significantly higher local and systemic adverse reaction rates than the control group. By booster vaccination, HD patients could acquire more effective SARS-CoV-2-specific humoral and cellular immunity than the control group.",

author = "Ayumi Yoshifuji and Masataro Toda and Munekazu Ryuzaki and Emi Oyama and Kan Kikuchi and Toru Kawai and Ken Sakai and Masayoshi Koinuma and Kazuhiko Katayama and Takashi Yokoyama and Yuki Uehara and Norio Ohmagari and Yoshihiko Kanno and Hirofumi Kon and Toshio Shinoda and Yaoko Takano and Junko Tanaka and Kazuhiko Hora and Yasushi Nakazawa and Naoki Hasegawa and Norio Hanafusa and Fumihiko Hinoshita and Keita Morikane and Shu Wakino and Hidetomo Nakamoto and Yoshiaki Takemoto",

note = "Publisher Copyright: {\textcopyright} 2023 by the authors.",

year = "2023",

month = mar,

doi = "10.3390/vaccines11030653",

language = "English",

volume = "11",

journal = "Vaccines",

issn = "2076-393X",

publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",

number = "3",

}

Yoshifuji, A, Toda, M, Ryuzaki, M, Oyama, E, Kikuchi, K, Kawai, T, Sakai, K, Koinuma, M, Katayama, K, Yokoyama, T, Uehara, Y, Ohmagari, N, Kanno, Y, Kon, H, Shinoda, T, Takano, Y, Tanaka, J, Hora, K, Nakazawa, Y, Hasegawa, N, Hanafusa, N, Hinoshita, F, Morikane, K, Wakino, S, Nakamoto, H & Takemoto, Y 2023, 'T-Cell Response and Antibody Production Induced by the COVID-19 Booster Vaccine in Japanese Chronic Kidney Disease Patients Treated with Hemodialysis', Vaccines, vol. 11, no. 3, 653. https://doi.org/10.3390/vaccines11030653

TY - JOUR

T1 - T-Cell Response and Antibody Production Induced by the COVID-19 Booster Vaccine in Japanese Chronic Kidney Disease Patients Treated with Hemodialysis

AU - Yoshifuji, Ayumi

AU - Toda, Masataro

AU - Ryuzaki, Munekazu

AU - Oyama, Emi

AU - Kikuchi, Kan

AU - Kawai, Toru

AU - Sakai, Ken

AU - Koinuma, Masayoshi

AU - Katayama, Kazuhiko

AU - Yokoyama, Takashi

AU - Uehara, Yuki

AU - Ohmagari, Norio

AU - Kanno, Yoshihiko

AU - Kon, Hirofumi

AU - Shinoda, Toshio

AU - Takano, Yaoko

AU - Tanaka, Junko

AU - Hora, Kazuhiko

AU - Nakazawa, Yasushi

AU - Hasegawa, Naoki

AU - Hanafusa, Norio

AU - Hinoshita, Fumihiko

AU - Morikane, Keita

AU - Wakino, Shu

AU - Nakamoto, Hidetomo

AU - Takemoto, Yoshiaki

PY - 2023/3

Y1 - 2023/3

N2 - Humoral and cellular responses are critical in understanding immune responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination. Here, we evaluated these responses in hemodialysis (HD) patients after the booster vaccination. SARS-CoV-2 immunoglobulin (IgG) levels, neutralizing antibody titers, and the T-SPOT®.COVID test (T-SPOT) were measured prior to, three weeks after, and three months after the booster administration. The HD group had significantly higher SARS-CoV-2 IgG levels and neutralizing antibody titers against the original strain at three weeks and three months after the booster vaccination compared to the control group, albeit the HD group had lower SARS-CoV-2 IgG levels and neutralizing antibody titers before the booster administration. Moreover, the HD group had significantly higher T-SPOT levels at all three time points compared to the control group. The HD group also had significantly higher local and systemic adverse reaction rates than the control group. By booster vaccination, HD patients could acquire more effective SARS-CoV-2-specific humoral and cellular immunity than the control group.

AB - Humoral and cellular responses are critical in understanding immune responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination. Here, we evaluated these responses in hemodialysis (HD) patients after the booster vaccination. SARS-CoV-2 immunoglobulin (IgG) levels, neutralizing antibody titers, and the T-SPOT®.COVID test (T-SPOT) were measured prior to, three weeks after, and three months after the booster administration. The HD group had significantly higher SARS-CoV-2 IgG levels and neutralizing antibody titers against the original strain at three weeks and three months after the booster vaccination compared to the control group, albeit the HD group had lower SARS-CoV-2 IgG levels and neutralizing antibody titers before the booster administration. Moreover, the HD group had significantly higher T-SPOT levels at all three time points compared to the control group. The HD group also had significantly higher local and systemic adverse reaction rates than the control group. By booster vaccination, HD patients could acquire more effective SARS-CoV-2-specific humoral and cellular immunity than the control group.

UR - http://www.scopus.com/inward/record.url?scp=85151923192&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85151923192&partnerID=8YFLogxK

U2 - 10.3390/vaccines11030653

DO - 10.3390/vaccines11030653

M3 - Article

AN - SCOPUS:85151923192

SN - 2076-393X

VL - 11

JO - Vaccines

JF - Vaccines

IS - 3

M1 - 653

ER -

T-Cell Response and Antibody Production Induced by the COVID-19 Booster Vaccine in Japanese Chronic Kidney Disease Patients Treated with Hemodialysis

Abstract

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this